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BACKGROUND: Refractory hypoglycemia in patients with metastatic insulinoma is
an important cause of morbidity and mortality. Everolimus could be a new
therapeutic option.
METHODS: Within the French Group, we conducted a retrospective, multicentric
study of endocrine tumors to evaluate the time to the first recurrence of
symptomatic hypoglycemia, after everolimus initiation, in patients with metastatic
insulinoma and refractory hypoglycemia. Ongoing hyperglycemic medical options,
tumor response, and safety information were recorded.
RESULTS: Twelve patients with metastatic insulinoma and refractory
hypoglycemia who were treated with everolimus between May 2007 and June 2011
were reviewed. Everolimus (starting dose, 10 mg/day, except in one patient, 5
mg/day) was given after a median of four previous therapeutic lines. Medication
aimed at normalizing blood glucose levels in 11 patients. After a median duration of
6.5 months (range 1-35+ months), median time to the first recurrence of
symptomatic hypoglycemia was 6.5 months (range 0 to 35+ months). Three patients
discontinued everolimus because of cardiac and/or pulmonary adverse events at 1,
1.5, and 7 months after initiation, which led to two deaths. Three patients
discontinued everolimus because of tumor progression at 2, 3, and 10 months after
initiation, without recurrence of hypoglycemia.
CONCLUSION: Everolimus appears to be a new effective treatment for patients
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